4,6-壬烷二酮 | 14090-88-1

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4,6-壬烷二酮
• 中文别名: 壬烷-4,6-二酮
• 英文名称: 4,6-Nonanedione
• 英文别名: Nonane-4,6-dione
• CAS: 14090-88-1
• 化学式: C₉H₁₆O₂
• mdl: MFCD00041931
• 分子量: 156.225
• InChiKey: ZDYWPVCQPUPOJV-UHFFFAOYSA-N

物化性质

• 熔点：
  -46 °C
• 沸点：
  79-81°C 8mm
• 密度：
  0.9181 g/cm3(Temp: 16 °C)
• 保留指数：
  1152

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2914190090

SDS

Name:	4 6-Nonanedione 99% (gc) Material Safety Data Sheet
Synonym:
CAS:	14090-88-1

Section 1 - Chemical Product MSDS Name:4 6-Nonanedione 99% (gc) Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
14090-88-1	4,6-nonanedione		237-938-7

Hazard Symbols: Not available.
Risk Phrases:

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Target Organs: None.
Potential Health Effects
The toxicological properties of this material have not been investigated. Use appropriate procedures to prevent opportunities for direct contact with the skin or eyes and to prevent inhalation.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
Remove contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Keep container closed when not in use.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits +--------------------+-------------------+-------------------+-----------------+ | Chemical Name | ACGIH | NIOSH |OSHA - Final PELs| |--------------------|-------------------|-------------------|-----------------| | 4,6-nonanedione |200 ppm TWA |200 ppm TWA; 1050 |none listed | | | (listed under ** |mg/m3 TWA | | | |no name **). | (listed under ** | | | | |no name **). | | +--------------------+-------------------+-------------------+-----------------+ OSHA Vacated PELs: 4,6-nonanedione: 200 ppm TWA; 1050 mg/m3 TWA (listed under ** no name **) Personal Protective Equipment Eyes: Wear chemical goggles.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant a respirator's use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Not available.
Appearance: clear light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 80 deg C @ 8.00mm Hg
Freezing/Melting Point: 0 deg C
Autoignition Temperature: Not available.
Flash Point: 80 deg C ( 176.00 deg F)
NFPA Rating: Not published.
Explosion Limits, Lower: Not available.
Upper: Not available.
Decomposition Temperature:
Solubility:
Specific Gravity/Density:
Molecular Formula: C9H16O2
Molecular Weight: 156.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Not available.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 14090-88-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4,6-nonanedione - Not listed by ACGIH, IARC, NIOSH, NTP, or OSHA.
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Chemical waste generators must determine whether a discarded chemical is classif as a hazardous waste.
US EPA guidelines for the classification determination are listed in 40 CFR Part Additionally, waste generators must consult state and local hazardous waste regu ensure complete and accurate classification.
RCRA P-Series: None listed.
RCRA U-Series: None listed.

---

Section 14 - TRANSPORT INFORMATION

CDG/CPL
Not classified as hazardous for supply.
Canadian TDG
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 14090-88-1: No information available.
United Kingdom Occupational Exposure Limits
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
WHMIS: Not available.
CAS# 14090-88-1 is not listed on Canada's Ingredient Disclosure List.
Exposure Limits
CAS# 14090-88-1 (listed as ** undefined **): OEL-DENMARK:TWA 200 ppm (
1050 mg/m3)
OEL-FINLAND:TWA 200 ppm (1050 mg/m3);STEL 250 ppm (1315 mg/m3)
OEL-FRANCE:TWA 200 ppm (1050 mg/m3)
OEL-THE NETHERLANDS:TWA 200 ppm (1050 mg/m3) JAN9
OEL-SWITZERLAND:TWA 200 ppm (1050 mg/m3)
OEL IN BULGARIA, COLOMBIA, JORDAN, KOREA check ACGIH TLV
OEL IN NEW ZEALAND, SINGAPORE, VIETNAM check ACGI TLV
US FEDERAL
TSCA
CAS# 14090-88-1 is listed on the TSCA inventory.
Health & Safety Reporting List
None of the chemicals are on the Health & Safety Reporting List.
Chemical Test Rules
None of the chemicals in this product are under a Chemical Test Rule.
Section 12b
None of the chemicals are listed under TSCA Section 12b.
TSCA Significant New Use Rule
None of the chemicals in this material have a SNUR under TSCA.
SARA
Section 302 (RQ)
None of the chemicals in this material have an RQ.
Section 302 (TPQ)
None of the chemicals in this product have a TPQ.
Section 313
No chemicals are reportable under Section 313.
Clean Air Act:
This material does not contain any hazardous air pollutants.
This material does not contain any Class 1 Ozone depletors.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,6-壬烷二酮 在 sodium tetrahydroborate 、 氨 、 sodium 作用下， 以 四氢呋喃 为溶剂， 生成 (S)-4-壬醇
  参考文献：
  名称：

  Schlosser,M.; Fouquet,G., Chemische Berichte, 1974, vol. 107, p. 1162 - 1170

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(呋喃-2-基甲基)呋喃 在 platinum on activated charcoal 氢气 作用下， 生成 4,6-壬烷二酮
  参考文献：
  名称：

  Preparation of aliphatic diketones by hydrogenolysis of difurylalkanes and difurylalkenes

  摘要：

  DOI：

  10.1007/bf01199652

文献信息

• Enantioselective Preparation of 2,4-Disubstituted Azetidines
  作者：Angela Marinetti、Philippe Hubert、Jean-Pierre Genêt

  DOI：10.1002/(sici)1099-0690(200005)2000:9<1815::aid-ejoc1815>3.0.co;2-8

  日期：2000.5

  Chiral C2-symmetric N-benzylazetidines have been conveniently prepared from optically pure anti-1,3-diols without loss of enantiomeric purity. N-Debenzylation led to the corresponding N-unsubstituted azetidines, which were then subjected to palladium-catalysed coupling reactions with aryl bromides to afford chiral N-arylazetidines. (R,R)-N-Benzyl-2,4-dimethylazetidine has been employed in the synthesis

  手性 C2 对称 N-苄基氮杂环丁烷可以方便地从光学纯的抗 1,3-二醇制备，而不会损失对映体纯度。N-脱苄基化生成相应的 N-未取代氮杂环丁烷，然后将其与芳基溴化物进行钯催化偶联反应，得到手性 N-芳基氮杂环丁烷。(R,R)-N-Benzyl-2,4-二甲基氮杂环丁烷已用于合成新的环钯络合物，例如，可用作磷配体的手性识别剂。
• DNA Methyltransferase inhibitors
  申请人：The Penn State Research Foundation

  公开号：EP1420021A1

  公开（公告）日：2004-05-19

  A compound of the formula or a pharmaceutically acceptable salt thereof, whereinR1, R2, and R3 are the same or different and are independently hydrogen, lower alkyl, aryl or substituted aryl, lower alkoxy, lower alkoxyalkyl, or cycloalkyl or cycloalkyl alkoxy, where each cycloalkyl group has from 3-7 members, where up to two of the cycloalkyl members are optionally hetero atoms selected from oxygen and nitrogen, and where any member of the alkyl, aryl or cycloalkyl group is optionally substituted with halogen, lower alkyl or lower alkoxy, aryl or substituted aryl, and whereR3 can be ribose, deoxyribose or phosphorylated derivatives thereof, whereinR1, R2, and R3 are not all hydrogen and whereinwhen R3 is ribose, deoxyribose or phosphorylated derivatives thereof, one of R1 or R2 is not hydrogen.

  该化合物的结构式为 或其药用可接受盐， 其中R1、R2和R3相同或不同，且独立地为氢、较低烷基、芳基或取代芳基、较低烷氧基、较低烷氧基烷基、环烷基或环烷基烷氧基，其中每个环烷基团具有3-7个成员，其中最多两个环烷基成员可选择为氧和氮，且烷基、芳基或环烷基团的任何成员可选择地取代有卤素、较低烷基或较低烷氧基、芳基或取代芳基，以及 其中R3可以是核糖、脱氧核糖或其磷酸化衍生物， 其中R1、R2和R3不全为氢， 当R3为核糖、脱氧核糖或其磷酸化衍生物时，R1或R2中的一个不是氢。
• Treatment of bacterial induced diseases using DNA methyl transferase inhibitors
  申请人：Benkovic J. Stephen

  公开号：US20050227933A1

  公开（公告）日：2005-10-13

  Methods for treating and/or preventing disease conditions caused or induced or aggravated by microbes, especially bacteria, by inhibiting DNA methyltransferase activity, such as by administering to an animal a DNA methyltransferase inhibitor, are disclosed, along with methods of reducing or ablating virulence in bacteria by inhibiting DNA methyltransferase activity.

  通过抑制DNA甲基转移酶活性，例如通过向动物施用DNA甲基转移酶抑制剂，来治疗和/或预防由微生物，特别是细菌引起、诱导或加重的疾病状况的方法被揭示，同时还揭示了通过抑制DNA甲基转移酶活性来减少或消除细菌的毒力的方法。
• COBALT COMPLEX, METHOD FOR MANUFACTURING SAME, AND METHOD FOR MANUFACTURING COBALT-CONTAINING THIN FILM
  申请人：TOSOH CORPORATION

  公开号：US20220017553A1

  公开（公告）日：2022-01-20

  To provide a cobalt complex which is liquid at room temperature, useful for producing a cobalt-containing thin film under conditions without using an oxidizing gas. A cobalt complex represented by the following formula (1): L 1 -Co-L 2 (1) wherein L 1 and L 2 represent a unidentate amide ligand of the following formula (A), a bidentate amide ligand of the following formula (B) or a hetero atom-containing ligand of the following formula (C): wherein R 1 and R 2 represent a C 1-6 alkyl group or a tri(C 1-6 alkyl)silyl group, and the wave line represents a binding site to the cobalt atom; wherein R 3 represents a tri(C 1-6 alkyl)silyl group, R 4 and R 5 represent a C 1-4 alkyl group, and X represents a C 1-6 alkylene group; wherein R 6 and R 8 represent a C 1-6 alkyl group, R 7 represents a hydrogen atom or a C 1-4 alkyl group, Y represents an oxygen atom or NR 9 , Z represents an oxygen atom or NR 10 , and R 9 and R 10 independently represent a C 1-6 alkyl group.

  提供一种在室温下为液体的钴配合物，可用于在不使用氧化气体的条件下制备含钴薄膜。 由以下式（1）表示的钴配合物： L1-Co-L2（1） 其中L1和L2表示以下式（A）的单齿酰胺配体，以下式（B）的双齿酰胺配体或以下式（C）的含杂原子配体： 其中R1和R2表示C1-6烷基或三(C1-6烷基)硅基团，波浪线表示与钴原子的结合位点； 其中R3表示三(C1-6烷基)硅基团，R4和R5表示C1-4烷基，X表示C1-6亚烷基团； 其中R6和R8表示C1-6烷基，R7表示氢原子或C1-4烷基，Y表示氧原子或NR9，Z表示氧原子或NR10，R9和R10独立表示C1-6烷基。
• 5-(4-Thiazolyl)-6-alkyl-2(1H)-pyridinones and their cardiotonic use
  申请人：Sterling Drug Inc.

  公开号：US04469699A1

  公开（公告）日：1984-09-04

  3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-thiazolyl)-6-R.sub.1 -2(1H)-pyridinones (I), where R.sub.1 is alkyl having from one to four carbon atoms, R.sub.2 is hydrogen or methyl, R.sub.3 is hydrogen or alkyl having from one to three carbon atoms, Q is amino, carbamyl, carboxy, cyano or hydrogen, and Q' is alkyl having from one to four carbon atoms, amino or R.sub.4 NH where R.sub.4 is alkyl having from one to four carbon atoms, or acid-addition salts thereof where at least one of Q and Q' is amino or Q' is R.sub.4 NH, are useful as cardiotonics (I where Q is amino, cyano or hydrogen) and/or as intermediates (I where Q is cyano, carbamyl or carboxy). Also shown as intermediates are 1,2-dihydro-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-oxo-3-pyridinecarbonitriles (II), and, also, processes for preparing I and II.

  3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-thiazolyl)-6-R.sub.1 -2(1H)-pyridinones (I)，其中R.sub.1是具有一到四个碳原子的烷基，R.sub.2是氢或甲基，R.sub.3是氢或具有一到三个碳原子的烷基，Q是氨基、氨基甲酰基、羧基、氰基或氢，Q'是具有一到四个碳原子的烷基、氨基或R.sub.4 NH，其中R.sub.4是具有一到四个碳原子的烷基，或其酸盐加合物，其中Q和Q'中至少有一个是氨基或Q'是R.sub.4 NH，可用作心力补充剂（其中Q是氨基、氰基或氢）和/或作为中间体（其中Q是氰基、氨基甲酰基或羧基）。 还显示了1,2-二氢-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-氧代-3-吡啶腈（II）作为中间体，以及制备I和II的方法。

表征谱图